RedHill Biopharma Ltd. provided earnings guidance for the quarter ended September 30, 2021. For the period, the company estimates its total net revenues were in the range of $21 million to $22 million, compared to $20.9 million in the quarter ended September 30, 2020. The Company further estimates that its operating loss in the range of $17 million to $19 million, compared to $14.5 million in the quarter ended September 30,2020. The above estimated revenues and operating loss for the quarter ended September 30, 2021, reflect company’s current preliminary review, which is still ongoing and could result in changes to the estimated revenues and operating loss figures.